rituximab
nounUS /ɹɪˈtʌk.sɪˌmæb/
Etymology From [Term?] + -tu- (“tumor”) + -ximab (“chimeric monoclonal antibody”).
1
Medicine, Pharmacology, Sciences Usually A chimeric monoclonal antibody (trademark Rituxan) administered by intravenous injection especially to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia by binding to the protein CD20 found on the surface of B cells and causing their lysis.